antisense oligonucleotide

Dynacure launches with $55 million and Ionis antisense oligonucleotide drug

The French startup will develop an RNA-targeted therapy for the rare muscle disease centronuclear myopathy




antisense oligonucleotide

Antisense oligonucleotides for inducing exon skipping and methods of use thereof

An antisense molecule capable of binding to a selected target site to induce exon skipping in the dystrophin gene, as set forth in SEQ ID NO: 1 to 202.




antisense oligonucleotide

Dynacure launches with $55 million and Ionis antisense oligonucleotide drug

The French startup will develop an RNA-targeted therapy for the rare muscle disease centronuclear myopathy